SGLT2 Inhibitor Protective Effects in Lupus Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D). https://t.co/I5ZrA9pXRU https://t.co/8U0ILPbMuN